Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
Latest Information Update: 25 Oct 2024
At a glance
- Drugs Cetuximab (Primary) ; Docetaxel (Primary) ; Magrolimab (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 30 Aug 2024 As per ClinicalTrials.gov, Reason the study was terminated due to Slow Accrual
- 30 Aug 2024 Status changed from suspended to discontinued.
- 01 Mar 2024 Status changed from recruiting to suspended.